Rasio utang jangka dawa marang modal adlainortye.com (ANL)

Adlai Nortye Limited - logo grafis emiten ANL

The planned capital reduction of Adlai Nortye Ltd. (ANL) may be cause for concern, however, the long-term debt-to-equity ratio on the GURU.Markets terminal linear chart shows that the value has stabilized at 0.04. This confirms the bet on buparlisib to capture the oncology market. Adlai Nortye Ltd. revenues will be based on insurance payouts for innovative head and neck cancer therapy.

Utang jangka dawa marang modal: Adlai Nortye Ltd (ANL) kanggo 21.02.2024 - 01.11.2026
Barang unggulan Adlai Nortye Ltd.

This ratio measures the proportion of long-term liabilities relative to equity, determining the business's degree of dependence on external financing. The metric's trend allows for an assessment of the company's resilience to credit risks and the efficiency of its financial leverage. By analyzing the ratio of long-term debt to equity, an investor can track the evolution of the liability structure. A decrease in this indicator minimizes default risk. Stable borrowing supports the development of the global oncology pipeline of Adlai Nortye (ANL) across various jurisdictions.

Perusahaan pesaing

Utang jangka dawa marang modal BeiGene Ltd.|Utang jangka dawa marang ekuitas Halozyme Inc. (HALO)|Revolution Medicines Corp - Rasio utang jangka dawa marang modal|Utang jangka dawa marang modal AAPG (Ascentage Pharma Group)|CGON - Rasio utang jangka dawa marang ekuitas|UroGen Pharma - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Bicara Therapeutics Inc|Personalis Corp (PSNL) - Utang jangka dawa marang ekuitas|Erasca Oncology - Koefisien utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas DCTH|YMAB: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal AURA|Rasio utang jangka dawa marang ekuitas candeltx.com CADL|Accuray Inc. - Rasio utang jangka dawa marang ekuitas|Utang jangka dawa marang modal SELLAS Life Sciences Group, Inc. SLS|ACTU - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal CTOR (citiusonc.com)|HURA: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Protara Therapeutics Inc (TARA)|FATE (Fate Therapeutics Corp) - Utang jangka dawa marang modal|Utang jangka dawa marang modal Aadi Bio|Utang jangka dawa marang modal TCRX|championsoncology.com - Rasio utang jangka dawa marang modal|Utang jangka dawa marang ekuitas XBiotech XBIT|CEL-SCI Corp. - Utang jangka dawa marang ekuitas|OS Therapies Inc - Utang jangka dawa marang modal|RADX - Utang jangka dawa marang modal|ARTV: Utang jangka dawa marang modal|VERU - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas TPST|XLO: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Renovaro Inc. (RENB)|muraloncology.com - Rasio utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Kairos Pharma KAPA|OnKure Therapeutics, Inc. (OKUR) - Kewajiban jangka dawa marang modal|GDTC - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Rasio utang jangka dawa marang ekuitas|THAR: Rasio silihan jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas ADVB|Kewajiban jangka dawa marang modal genprex.com GNPX|Utang jangka dawa marang modal CLDI|SBFM - Kewajiban jangka dawa marang modal|Xenetic Biosciences, Inc. - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal SLRX|PPBT - Utang jangka dawa marang ekuitas|AONC: Utang jangka dawa marang ekuitas|BGNE (BeiGene) - Rasio utang jangka dawa marang ekuitas|CKPT: Rasio silihan jangka dawa marang modal|ELEV (Elevation Oncology, Inc.) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal ICAD (iCAD Corp)|Rasio utang jangka dawa marang ekuitas IKNA (Ikena Oncology, Inc.)|Rasio tanggungan utang jangka dawa marang modal notablelabs.com|Utang jangka dawa marang modal VIRX (Viracta Therapeutics, Inc.)|Utang jangka dawa marang modal MorphoSys Inc MOR|NAYA - Utang jangka dawa marang ekuitas|AAPGV (Ascentage) - Rasio utang jangka dawa marang modal